Related Experiment Video
Updated: Aug 3, 2026
11:29
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
[Prion disease and brain amyloidosis]
V S Rukosuev1, A A Zhavoronkov
1Research Institute of Human Morphology, Moscow.
Arkhiv Patologii
|July 21, 1999
Summary
Human prion diseases like CJD involve abnormal prion proteins (PrPres) causing neurodegeneration. Researchers found that Congo-red and sulfated glycans can inhibit PrPres formation, offering potential therapeutic strategies.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Context:
- Human prion disorders encompass Kuru, Creutzfeld-Jakob disease (CJD), Gerstman-Straussler-Scheinkler syndrome (GSS), fatal familial insomnia (FFI), and prion protein cerebral amyloid angiopathy (PrPCAA).
- These diseases present as infectious, genetic, or sporadic conditions, all involving an abnormal, protease-resistant prion protein (PrPres).
- The normal host prion protein (PrPsen) is encoded by the PRNP gene on chromosome 20, with 19 mutations identified causing inherited prion diseases.
Purpose:
- To elucidate the molecular mechanisms underlying prion protein conformational changes and amyloidogenesis.
- To investigate the role of PrPres in neurotoxicity and neuropathological events.
- To explore potential therapeutic interventions targeting PrPres formation.
Summary:
- Prion diseases are characterized by the conversion of normal prion protein (PrPsen) to an abnormal, protease-resistant form (PrPres).
- This conversion involves a shift from alpha-helix to beta-sheet structures, leading to PrP-amyloidogenesis, particularly evident in GSS.
- Pathomorphologically, brain amyloidogenesis manifests as PrPres conglomerates and amyloid plaques, with PrPres neurotoxicity supporting its causal role in disease pathogenesis.
- Congo-red and specific sulfated glycans demonstrate potent inhibition of PrPres formation, indicating therapeutic potential.
Impact:
- Understanding PrPres formation and inhibition provides a basis for developing novel therapeutic strategies for human prion disorders.
- Identifying key molecular pathways involved in prion disease pathogenesis can accelerate drug discovery.
- This research contributes to the broader field of protein misfolding diseases and neurodegenerative disorders.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...